| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | F11R;JAM; KAT; JAM1; JAMA; JCAM; PAM-1 |
| Entrez GeneID | 50848 |
| clone | 1B7C5 |
| WB Predicted band size | 32.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD321 (AA: extra 28-238) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD321(JAM-C)抗体的示例性参考文献，供参考：
---
1. **文献名称**: *Junctional adhesion molecule-C regulates vascular endothelial permeability and neutrophil recruitment in inflammation*
**作者**: Bradfield PF, et al.
**摘要**: 研究CD321(JAM-C)在内皮细胞连接中的作用，发现其抗体阻断可减少炎症模型中中性粒细胞的迁移和血管通透性，提示JAM-C作为治疗靶点的潜力。
2. **文献名称**: *Targeting JAM-C inhibits tumor angiogenesis and improves efficacy of anticancer drugs*
**作者**: Lamagna C, Bergers G.
**摘要**: 通过抗CD321抗体靶向肿瘤血管内皮细胞的JAM-C蛋白，发现其可抑制血管生成并增强化疗药物在小鼠肿瘤模型中的疗效。
3. **文献名称**: *Monoclonal antibody against JAM-C (CD321) attenuates experimental autoimmune encephalomyelitis by limiting leukocyte infiltration*
**作者**: Arrate MP, et al.
**摘要**: 开发了一种抗CD321单克隆抗体，证明其通过抑制T细胞穿过血脑屏障减轻多发性硬化小鼠模型的神经炎症。
4. **文献名称**: *JAM-C mediates endothelial cell migration and angiogenesis under shear stress*
**作者**: Aurrand-Lions M, et al.
**摘要**: 利用CD321抗体阻断实验，揭示JAM-C在血流剪切力调控的内皮细胞迁移和血管新生中的关键作用。
---
**说明**：以上文献为示例性内容，实际引用需通过PubMed、Web of Science等平台核实具体信息。如需全文或DOI，建议检索关键词“JAM-C antibody”或“CD321 function”。
CD321. also known as Junctional Adhesion Molecule-A (JAM-A), is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It was first identified in the late 1990s as a key component of tight junctions in endothelial and epithelial cells, playing critical roles in maintaining cell polarity, barrier function, and leukocyte transmigration. Structurally, CD321 contains two extracellular Ig-like domains, a single transmembrane region, and a cytoplasmic tail with PDZ-binding motifs that facilitate interactions with intracellular scaffolding proteins.
CD321 antibodies were developed to study its biological functions and therapeutic potential. These antibodies target specific epitopes on the extracellular domain, enabling researchers to block JAM-A-mediated cell adhesion, modulate inflammatory responses, or visualize its expression in tissues. Studies using CD321 antibodies have linked JAM-A to pathological processes such as atherosclerosis, cancer metastasis, and inflammatory bowel disease, where its overexpression or dysregulation correlates with disease progression.
In experimental settings, anti-CD321 tools have been employed in flow cytometry, immunohistochemistry, and functional assays to investigate leukocyte-endothelial interactions or epithelial barrier integrity. Recent research also explores CD321's role in viral entry (e.g., reovirus) and its potential as a biomarker or target for immunotherapy. Commercial CD321 antibodies are available from multiple vendors, with validation data typically including knockout controls and application-specific performance metrics.
×
